choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Lung Cancer & Xalkori

Lung Cancer & Xalkori Newsletter
  • Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer 19 Dec 2024 20:01 GMT

    … -positive non-small cell lung cancer among patients who’ve … the first innovative targeted lung cancer drug developed by a … Lorbrena have all outperformed Xalkori to secure their respective … JAMA Oncology. Compared with Xalkori, Ensacove reduced the risk …

  • FDA approves ensartinib for metastatic non-small cell lung cancer 19 Dec 2024 19:40 GMT

    … metastatic non-small cell lung cancer. The indication applies to … or metastatic non-small cell lung cancer. Image: Adobe Stock. … positive non-small cell lung cancer who had not previously … received ensartinib or crizotinib (Xalkori, Pfizer). PFS served as …

  • FDA Approves Ensartinib for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer 19 Dec 2024 19:10 GMT

    … Positive Non-Small Cell Lung Cancer (NSCLC) Patients ClinicalTrials … metastatic non–small cell lung cancer (NSCLC) who have … ensartinib compared with crizotinib (Xalkori; Pfizer). A total … Positive Non-Small Cell Lung Cancer (NSCLC) Patients. ClinicalTrials …

  • China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC 20 Dec 2024 19:09 GMT

    … ROS1-positive non–small cell lung cancer (NSCLC) who have been previously … received prior treatment with crizotinib (Xalkori; n = 66), taletrectinib produced a … metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I …

  • FDA Approves Ensacove for ALK-Positive NSCLC 19 Dec 2024 00:48 GMT

    … randomized to receive Ensacove or Xalkori (crizotinib). Glossary: Progression … patients with ALK-positive lung cancer currently living in the … of patients treated with Xalkori. “In this randomized … intracranial efficacy compared with [Xalkori] and an overall …

  • FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC 19 Dec 2024 00:23 GMT

    … metastatic non–small cell lung cancer (NSCLC) who have … receive ensartinib or crizotinib (Xalkori). The primary end point … or metastatic non-small cell lung cancer. FDA. December 18, … ALK positive non-small cell lung cancer (NSCLC) patients. ClinicalTrials. …

  • Pharmac Consulting On Six Medicines For New Zealanders 19 Dec 2024 00:24 GMT

    … as Xalkori) for a type of advanced non-small cell lung cancer with …

  • FDA Approves Ensartinib To Treat Frontline ALK+ NSCLC 18 Dec 2024 21:51 GMT

    … or metastatic non-small cell lung cancer (NSCLC) who have not … than compared with crizotinib (Xalkori) at 25.8 months … or metastatic non-small cell lung cancer. News release. FDA. … kinase−positive non–small cell lung cancer: a randomized clinical trial. …

  • FDA Approves Ensartinib in Metastatic ALK-Positive NSCLC 18 Dec 2024 21:11 GMT

    … ALK-positive non–small cell lung cancer (NSCLC), according to … -positive NSCLC vs crizotinib (Xalkori). Topline data showed a … or metastatic non-small cell lung cancer. News release. FDA. … kinase-positive non-small cell lung cancer: a randomized clinical trial …

  • Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials 17 Dec 2024 17:39 GMT

    … approved by the FDA: crizotinib [Xalkori] and entrectinib [Rozlytrek],” Jessica Lin … for the Study of Lung Cancer World Conference on Lung Cancer (WCLC), investigators presented … ROS1-positive non-small cell lung cancer. News release. AnHeart Therapeutics. …

Satisfied with the content?

Continue to create your account.